Bicara Therapeutics to Participate in Upcoming Investor Conferences
Bicara Therapeutics (Nasdaq: BCAX), a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for solid tumors, has announced its participation in three major upcoming healthcare investor conferences in September 2025.
The company will present at the Cantor Global Healthcare Conference (September 3, 10:55 a.m. ET), the Wells Fargo Healthcare Conference (September 3, 2:15 p.m. ET), and the Morgan Stanley Global Healthcare Conference (September 8, 4:05 p.m. ET). All fireside chat presentations will be available via webcast through Bicara's Investor Relations website.
Bicara Therapeutics (Nasdaq: BCAX), azienda biofarmaceutica in fase clinica specializzata nello sviluppo di terapie bifunzionali per tumori solidi, ha annunciato la sua partecipazione a tre importanti conferenze per investitori nel settore sanitario previste per settembre 2025.
L'azienda terrà presentazioni alla Cantor Global Healthcare Conference (3 settembre, 10:55 ET), alla Wells Fargo Healthcare Conference (3 settembre, 14:15 ET) e alla Morgan Stanley Global Healthcare Conference (8 settembre, 16:05 ET). Tutti i colloqui in formato fireside chat saranno trasmessi in webcast attraverso il sito Investor Relations di Bicara.
Bicara Therapeutics (Nasdaq: BCAX), compañía biofarmacéutica en etapa clínica centrada en el desarrollo de terapias bifuncionales para tumores sólidos, ha anunciado su participación en tres importantes conferencias para inversores del sector sanitario en septiembre de 2025.
La compañía presentará en la Cantor Global Healthcare Conference (3 de septiembre, 10:55 ET), en la Wells Fargo Healthcare Conference (3 de septiembre, 14:15 ET) y en la Morgan Stanley Global Healthcare Conference (8 de septiembre, 16:05 ET). Todas las charlas tipo fireside chat estarán disponibles en webcast a través del sitio web de Relaciones con Inversores de Bicara.
Bicara Therapeutics (Nasdaq: BCAX)는 고형암용 이중기능 치료제 개발에 주력하는 임상 단계의 바이오제약사로, 2025년 9월에 열리는 주요 헬스케어 투자자 컨퍼런스 세 곳에 참가한다고 발표했습니다.
회사는 Cantor Global Healthcare Conference(9월 3일, 오전 10:55 ET), Wells Fargo Healthcare Conference(9월 3일, 오후 2:15 ET), Morgan Stanley Global Healthcare Conference(9월 8일, 오후 4:05 ET)에서 발표를 진행합니다. 모든 파이어사이드 채팅 발표는 Bicara 투자자 관계 웹사이트를 통해 웹캐스트로 시청할 수 있습니다.
Bicara Therapeutics (Nasdaq: BCAX), société biopharmaceutique en phase clinique spécialisée dans le développement de thérapies bifonctionnelles pour les tumeurs solides, a annoncé sa participation à trois grandes conférences investisseurs du secteur de la santé en septembre 2025.
La société présentera lors de la Cantor Global Healthcare Conference (3 septembre, 10h55 ET), de la Wells Fargo Healthcare Conference (3 septembre, 14h15 ET) et de la Morgan Stanley Global Healthcare Conference (8 septembre, 16h05 ET). Toutes les interventions en format "fireside chat" seront diffusées en webcast sur le site Investor Relations de Bicara.
Bicara Therapeutics (Nasdaq: BCAX), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung bifunktionaler Therapien für solide Tumoren spezialisiert hat, hat seine Teilnahme an drei wichtigen Investorenkonferenzen im Gesundheitswesen im September 2025 angekündigt.
Das Unternehmen wird auf der Cantor Global Healthcare Conference (3. September, 10:55 Uhr ET), der Wells Fargo Healthcare Conference (3. September, 14:15 Uhr ET) und der Morgan Stanley Global Healthcare Conference (8. September, 16:05 Uhr ET) präsentieren. Alle Fireside-Chat-Präsentationen werden per Webcast über die Investor-Relations-Website von Bicara verfügbar sein.
- None.
- None.
BOSTON, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that management will participate in multiple upcoming investor conferences:
- Cantor Global Healthcare Conference 2025
Date and Time: Wednesday, September 3, 2025 at 10:55 a.m. ET
- 2025 Wells Fargo Healthcare Conference
Date and Time: Wednesday, September 3, 2025 at 2:15 p.m. ET
- Morgan Stanley 23rd Annual Global Healthcare Conference
Date and Time: Monday, September 8, 2025 at 4:05 p.m. ET
Live webcasts of the fireside chats will be accessible through the Investor Relations section of Bicara’s website under Events and Presentations. Replays of the webcasts will be archived and available following each event.
About Bicara Therapeutics
Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Bicara’s lead program, ficerafusp alfa, is a first-in-class bifunctional antibody designed to drive tumor penetration by breaking barriers in the tumor microenvironment that have challenged the treatment of multiple solid tumor cancers. Specifically, ficerafusp alfa combines two clinically validated targets: an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-β). Through this targeted mechanism, ficerafusp alfa reverses the fibrotic and immune-excluded tumor microenvironment driven by TGF-β signaling to enable tumor penetration that drives deep and durable responses. Ficerafusp alfa is being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need, as well as other solid tumor types. For more information, please visit www.bicara.com or follow us on LinkedIn or X.
Contacts
Investors
Rachel Frank
IR@bicara.com
Media
Amanda Lazaro
1AB
Amanda@1abmedia.com
FAQ
When is Bicara Therapeutics (BCAX) presenting at the Cantor Global Healthcare Conference 2025?
How can investors access Bicara Therapeutics' (BCAX) conference presentations?
What type of company is Bicara Therapeutics (BCAX)?
Which investor conferences will Bicara Therapeutics (BCAX) attend in September 2025?
